丙肝治疗的研究进展幻灯片.pptVIP

* tpcr09_t Slide 14. Treatment duration has a greater impact than induction dosing on rate of SVR Although the rate of SVR was higher for the pooled induction arms versus the pooled non-induction arms the difference was not statistically significant (p=0.92; OR 0.98 [95% CI 0.63-1.51]). Extending the duration of treatment to 72 weeks resulted in a significant increase in SVR. Sixteen percent of patients treated for 72 weeks (Groups A and C pooled) achieved SVR compared with 8% treated with standard of care (Groups B and D pooled) (p=0.0006; odds ratio 2.22 [95% CI 1.40–3.52]). Jensen D, et al. 58th AASLD 2007; Abstract LB4 Slide 14. Treatment duration has a greater impact than induction dosing on rate of SVR Although the rate of SVR was higher for the pooled induction arms versus the pooled non-induction arms the difference was not statistically significant (p=0.92; OR 0.98 [95% CI 0.63-1.51]). Extending the duration of treatment to 72 weeks resulted in a significant increase in SVR. Sixteen percent of patients treated for 72 weeks (Groups A and C pooled) achieved SVR compared with 8% treated with standard of care (Groups B and D pooled) (p=0.0006; odds ratio 2.22 [95% CI 1.40–3.52]). Jensen D, et al. 58th AASLD 2007; Abstract LB4 * * * VX05-950-104EU Start announced in June 2006 (PR 23.05.2006) Press release 27.10.2006: Enrolment expected to be completed by year-end 2006 * VX06-950-106 Enrollment completed in 06/2007 In the NR group also null responders are included * Slightly lower numbers for rash than at EASL 09 * * Slide 5. ACHIEVE studies: design ACHIEVE 1: HCV genotype 1.1 ACHIEVE 2/3: HCV genotypes 2 and 3.2 Patients were randomised to 900 or 1200 μg albinterferon alfa-2b (Alb-IFN α-2b) q2W plus RBV 800 mg/day or PEGASYS? 180 μg/week plus RBV 1000/1200 mg/day Patients on 1200 μg Alb-IFN α-2b were switched to 900 μg Alb-IFN α-2b The rationale of the 1200 μg dose was to potentially improve antiviral activity The three cohorts were stratified by: HCV RNA